ZLNA ZELLUNA ASA

Zelluna ASA: Disclosure of large shareholding

Zelluna ASA: Disclosure of large shareholding

In accordance with the Norwegian Securities Trading Act Section 4-3, Inven2 AS ( “Inven2” ) hereby notifies that its ownership interest in Zelluna ASA (“Zelluna”) has fallen below the 10% threshold following the share capital increase in Zelluna through the private placement on November 3rd 2025.

Previous shareholding : 10,79%

New shareholding : 9,01%

Total number of shares held: 2,207,034

The reduction in ownership is due to dilution as result of the private placement. Inven2 has not sold any shares.

This notification is submitted pursuant to section 4-3 of the Norwegian Securities Trading Act and the Osl rule Book II – Issuer Rules.



 



EN
04/11/2025

Underlying

ZLNAZELLUNA ASA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ZELLUNA ASA

 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna ASA – Mandatory notification of trade

Zelluna ASA – Mandatory notification of trade Oslo, Norway, 27 March 2026 - Anders Tuv, Managing Director in Radforsk Invest, and Chairperson and co-founder of Zelluna ASA (Zelluna), has today entered into an agreement with Radforsk Investeringsstiftelse (Radforsk) pursuant to which Mr. Tuv has been granted options (the Options) to acquire up to 200,000 shares held by Radforsk in Zelluna. Each Option provides a right to acquire one share in Zelluna from Radforsk at an exercise price of NOK 18.5 per share (subject to customary adjustments). The Options are immediately vested and may be exer...

March 27, 2026 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna to host Capital Markets Update 2026

Zelluna to host Capital Markets Update 2026 Oslo, Norway – 26 March 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, invites investors, analysts and other stakeholders to attend its Capital Markets Update on 14 April 2026 (11:30–13:00 CET). At the event the company will present progress on its TCR-NK off-the-shelf cell therapy platform and ongoing clinical activities, including perspectives on early clinical data and recent developments in the cell therapy field. The ...

March 26, 2026 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna ASA [ZLNA]: Notice of Annual General Meeting on 23 April 2026

Zelluna ASA [ZLNA]: Notice of Annual General Meeting on 23 April 2026 Oslo, 26 March 2026 - The Board of Directors hereby calls for the Annual General Meeting of Zelluna ASA at 09:00 CEST on 23 April 2026.  The General Meeting will be held electronically and all documents related to the Annual General Meeting are available at the Company’s website at  For further information, please contact: Anders Tuv, Chairman of the BoardEmail: Phone: Namir Hassan, Chief Executive OfficerEmail: Phone: Geir Christian Melen, Chief Financial OfficerEmail: Phone:   Attachments ...

March 26, 2026 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna ASA [ZLNA]: Annual Report 2025

Zelluna ASA [ZLNA]: Annual Report 2025 Oslo, Norway, 25 March 2026 - Zelluna ASA, a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, announces that the Board of Directors of Zelluna ASA has approved the Annual Report for 2025.  A PDF version of the Annual Report, as well as the report in European Single Electronic Format (ESEF), are attached to this release. The Annual Report is also available on the company's website: This information is subject to the disclosure requirements pursuant to Sectio...

March 25, 2026 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna inngår samarbeid med Etcembly for AI-drevet TCR-utvikling

Zelluna inngår samarbeid med Etcembly for AI-drevet TCR-utvikling Oslo, Norge, 9. mars 2026 – Zelluna (OSE: ZLNA) er et banebrytende selskap innen utvikling av allogene "off-the-shelf" T-cellereseptor-baserte naturlige dreperceller (TCR-NK) for behandling av solide kreftformer. Selskapet kunngjorde i dag et samarbeid med Etcembly Ltd, et bioteknologiselskap som anvender kunstig intelligens (AI) og avansert maskinlæring for optimalisering og utvikling av T-cellereseptorer (TCR). Høydepunkter: AI-drevet samarbeid for utvikling av KKLC1-rettede TCR-er til Zellunas TCR-NK-plattformBygger på v...

March 9, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch